Cold atmospheric plasma, a novel approach against bladder cancer, with higher sensitivity for the high-grade cell line by Tavares-da-Silva, Edgar et al.
biology
Article
Cold Atmospheric Plasma, a Novel Approach against Bladder
Cancer, with Higher Sensitivity for the High-Grade Cell Line
Edgar Tavares-da-Silva 1,2,3,4,*,† , Eurico Pereira 3,5,*,† , Ana S. Pires 2,3,5 , Ana R. Neves 3,5,6,
Catarina Braz-Guilherme 3,5,7, Inês A. Marques 2,3,5,8 , Ana M. Abrantes 2,3,5, Ana C. Gonçalves 2,3,9,
Francisco Caramelo 3,10 , Rafael Silva-Teixeira 3,5, Fernando Mendes 2,3,5,11 , Arnaldo Figueiredo 1,2,3,4 and




Pereira, E.; Pires, A.S.; Neves, A.R.;
Braz-Guilherme, C.; Marques, I.A.;
Abrantes, A.M.; Gonçalves, A.C.;
Caramelo, F.; Silva-Teixeira, R.; et al.
Cold Atmospheric Plasma, a Novel
Approach against Bladder Cancer,
with Higher Sensitivity for the
High-Grade Cell Line. Biology 2021,
10, 41. https://doi.org/10.3390/
biology10010041
Received: 14 December 2020
Accepted: 7 January 2021
Published: 9 January 2021
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional clai-
ms in published maps and institutio-
nal affiliations.
Copyright: © 2021 by the authors. Li-
censee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment
Genetics and Oncobiology (CIMAGO), University of Coimbra, 3000-548 Coimbra, Portugal;
ajcfigueiredo@gmail.com
2 Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra,
Portugal; pireslourenco@uc.pt (A.S.P.); inesafmarques@gmail.com (I.A.M.); mabrantes@fmed.uc.pt (A.M.A.);
acgoncalves@fmed.uc.pt (A.C.G.); fjmendes@estescoimbra.pt (F.M.); mfbotelho@fmed.uc.pt (M.F.B.)
3 Clinical Academic Center of Coimbra (CACC), 3000-548 Coimbra, Portugal;
ritamarneves@gmail.com (A.R.N.); catarinaguilherme_7@hotmail.com (C.B.-G.); fcaramelo@fmed.uc.pt (F.C.);
rafaelesteixeira@gmail.com (R.S.-T.)
4 Department of Urology and Renal Transplantation, Centro Hospitalar e Universitário de Coimbra (CHUC),
3004-561 Coimbra, Portugal
5 Biophysics Institute of Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR)
Area of Environment Genetics and Oncobiology (CIMAGO), University of Coimbra,
3000-548 Coimbra, Portugal
6 Project Development Office, Department of Mathematics and Computer Science, Eindhoven University of
Technology (TU/e), P.O. Box 513, 5600 MB Eindhoven, The Netherlands
7 Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
8 Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal
9 Laboratory of Oncobiology and Hematology and University Clinic of Hematology of Faculty of Medicine,
Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and
Oncobiology (CIMAGO), University of Coimbra, 3000-548 Coimbra, Portugal
10 Laboratory of Biostatistics and Medical Informatics of Faculty of Medicine, Coimbra Institute for Clinical and
Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO),
University of Coimbra, 3000-548 Coimbra, Portugal
11 Politécnico de Coimbra, ESTeSC, DCBL, Rua 5 de Outubro-SM Bispo, Apartado 7006,
3046-854 Coimbra, Portugal
* Correspondence: edtavares@fmed.uc.pt (E.T.-d.-S.); uc2015247456@student.uc.pt (E.P.)
† Both authors contributed equally for this work.
Simple Summary: Bladder cancer has a high incidence and mortality. Besides this, currently available
therapies for this type of cancer have low efficacy and show considerable adverse effects, urging
the need of new therapeutic approaches. Cold Atmospheric Plasma treatment presents itself as
a promising alternative, having demonstrated antitumor effects against several types of cancer.
The present work arises from a multidisciplinary team, namely, medical doctors and researchers,
in an attempt to find new therapeutic strategies to fight bladder cancer. Therefore, our main objective
is to evaluate Cold Atmospheric Plasma effects against bladder cancer, as well as the mechanisms by
which it exerts its effects. The results obtained demonstrate that Cold Atmospheric Plasma treatment
has a promising antitumor effect on bladder cancer, with higher sensitivity for the high-grade cell
line. This new approach using Cold Atmospheric Plasma for the treatment of bladder cancer presents
enormous clinical benefits, since it is able to selectively treat the tumor tissue, sparing the normal
urothelium, with an additional glaring positive economic impact, since it entails a decrease in the
cost of therapy in comparison with conventional therapeutic options.
Abstract: Antitumor therapies based on Cold Atmospheric Plasma (CAP) are an emerging medical
field. In this work, we evaluated CAP effects on bladder cancer. Two bladder cancer cell lines
were used, HT-1376 (stage III) and TCCSUP (stage IV). Cell proliferation assays were performed
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evaluating metabolic activity (MTT assay) and protein content (SRB assay). Cell viability, cell
cycle, and mitochondrial membrane potential (∆ψm) were assessed using flow cytometry. Reactive
oxygen and nitrogen species (RONS) and reduced glutathione (GSH) were evaluated by fluorescence.
The assays were carried out with different CAP exposure times. For both cell lines, we obtained a
significant reduction in metabolic activity and protein content. There was a decrease in cell viability,
as well as a cell cycle arrest in S phase. The ∆ψm was significantly reduced. There was an increase
in superoxide and nitric oxide and a decrease in peroxide contents, while GSH content did not
change. These results were dependent on the exposure time, with small differences for both cell lines,
but overall, they were more pronounced in the TCCSUP cell line. CAP showed to have a promising
antitumor effect on bladder cancer, with higher sensitivity for the high-grade cell line.
Keywords: cold atmospheric plasma; plasma medicine; bladder cancer; reactive oxygen and nitrogen
species; cell death
1. Introduction
Bladder cancer is the 11th cancer with the highest incidence in the world [1]. About
75% of all bladder tumors are superficial (pTa or pT1) and its treatment is based on
endoscopic surgery followed by, in most cases, adjuvant intravesical treatment [2]. This
therapeutic combination has undergone little changes in recent decades. In terms of
surgery, there are some novelties such as en bloc resections of the tumors [3], that could be
an alternative the classic transurethral resections [4] for some patients. However, in terms
of intravesical therapy, the therapeutic agents in use are the same since the 1980s, such
as mitomycin C and Bacillus Calmette-Guérin (BCG) [5,6]. In the European Association of
Urology Guidelines for non-muscular invasive bladder cancer [2], like in other guidelines,
a single instillation of mitomycin C is indicated postoperatively in most of these patients.
After the histology result, patients are classified according to risk (low, intermediate or
high). Low-risk patients only receive the postoperative single instillation of mitomycin
C. Intermediate risk will take adjuvant therapy with mitomycin C or BCG, according to
the therapeutic history and the type of lesions. For high-risk patients, BCG is the only
approved adjuvant therapy. Yet, in this group, there is a subgroup of very-high-risk
patients that can also be identified, for which the best strategy may be cystectomy. So,
intravesical therapeutic agents are of paramount importance in bladder cancer. However,
they have significant adverse effects, especially BCG, and progression/relapses are still
frequent [7–9]. Furthermore, in recent years there have been difficulties in having BCG
available. Therefore, there is a need to develop new, safe, and effective therapies for the
treatment of bladder cancer.
Plasma is frequently referred to as the fourth state of matter, being a partially ionized
gas composed of ions, electrons, and neutral particles [10–12]. Quasi-thermal plasmas
have been used in medicine for a long time, for example in electrosurgical instruments [13].
Recently, devices capable of producing plasma at room temperature have emerged, the
so-called Cold Atmospheric Plasma (CAP). This CAP has been studied for different uses,
such as sterilization of materials, wound healing, dental, or neoplasms treatment [14]. By
studying different in vitro and in vivo models, it has been shown that CAP is capable of
selectively treat neoplasms, sparing normal and healthy tissues [15–17]. Indeed, several
variables influence CAP selectivity, such as the different types of media used for the culture
of different cell lines. To eliminate any bias caused by these experimental variables, more
studies addressing this issue must be done. As far as it is known, its main mechanism of
action is the production of reactive oxygen and nitrogen species (RONS) [18,19] that leads
to an imbalance in the oxidative stress. CAP also induces depolarization of mitochondrial
membrane [20], cell cycle arrest [21], and epigenetic alterations [22], among others.
More recently, Plasma Activated Medium (PAM) has been described, a water-based
medium that is treated with CAP. PAM acquires characteristics similar to CAP, allowing
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the selective treatment of neoplasms [23], with two major advantages: (1) PAM can be
produced locally in each hospital and can be stored for a few days [24] and (2) its application
could easily be held by filling the bladder with PAM.
There are only two studies that demonstrate the effect of CAP on bladder cancer, one
in vitro [25] and the other in vivo [26]. However, if the application of CAP or PAM could
be able to selectively treat microscopic neoplastic foci, sparing normal urothelium, it is
easy to imagine the enormous benefits of its use. Besides that, local production capacity
would make it possible to overcome the difficulties that are currently felt in relation to the
availability of BCG. Although the desired endpoint is to use PAM as an adjuvant treatment
after resection of bladder tumors, as an alternative or adjuctive to mitomycin or BCG, first
it is necessary to establish the efficacy of plasma-based therapies in urothelial carcinoma.
In this work, we propose to study the effects of CAP on bladder cancer, particularly
in the high-risk/very-high-risk tumors because of high grade tumor (G3) or aggressive
variants, for which BCG therapy or even cystectomy are the standard of care. For this, two
bladder cancer cell lines were treated with CAP and its anti-tumor capacity were evaluated,
as well as the mechanisms by which it exerts its effects, starting from the mechanisms
proposed for CAP’s action.
2. Materials and Methods
2.1. Cell Culture
Human bladder cancer cell lines with different molecular characteristics and belong-
ing to different stages of the disease were used, the HT-1376 cell line (ATCC® CRL-1472™)
representative of grade III carcinoma and the TCCSUP cell line (ATCC® HTB-5™) repre-
sentative of grade IV urothelial carcinoma. The cell lines used were obtained from the
American Type Culture Collection (ATCC®, USA) and maintained in a humidified atmo-
sphere, 37 ◦C and 5% CO2. Both cell lines were cultured in Dulbecco’s Modified Eagle’s
Medium, DMEM (Sigma, D5648) supplemented with 1% antibiotic (Sigma, A5955), 0.25
mM sodium pyruvate (Gibco, 11360), and 10 or 5% FBS (fetal bovine serum) for HT1376 or
TCCSUP, respectively.
2.2. Cells Treatment
Our group developed a direct current electronic device [27–30] capable of generating
high output voltage through a sterilized needle with 0.9 mm of radius and 40 mm of length
(Microlance 3, Becton Dickinson, USA). When charged, the needle works as an open-air
single electrode CAP jet. The equipment was designed to produce an electrical discharge
between the tip of the needle and multiwell plates where cell cultures were seeded. An
electrically grounded needle was submerged in the culture media. In this arrangement,
the cultures act both as target and grounded electrode enabling the plasma generation.
The high voltage needle was placed 2 mm above the surface of the cell culture’s medium.
The electric current intensity recorded in the needle in a closed circuit was 33 ± 1 µA,
the calculated voltage was approximately 4000 ± 121 V and the frequency of pulses was
1000 ± 10 Hz, each pulse with 1.0 ± 0.1 ms of duration. Irradiation of the media did
not produce a statistically different alteration in pH media for any exposure time (60 s
of CAP treatment pH = 7.41 ± 0.037, 90 s of CAP treatment pH = 7.43 ± 0.061, 120 s of
CAP treatment pH = 7.49 ± 0.035, the results are expressed as the mean ± SEM of the pH
measurement at 20 ◦C) nor its temperature, which remained at 26.4 ± 1.043 ◦C after 120 s
of CAP treatment (data not shown).
For the proliferation assays, both cell lines were plated in a 24-well cell culture plate
at a concentration of 1 × 105 cell/mL in a volume of 500 µL/well. The cells were allowed
to adhere, and then were submitted to CAP treatment, which was generated in open-air,
2 mm above the surface of the cell culture medium, for 15, 30, 60, 90, and 120 s. Upon
24, 48, and 72 h after CAP treatment, metabolic activity was assessed by MTT assay and
protein content by SRB assay, to evaluate cell proliferation.
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The viability and cell death profile, the cell cycle, and the mitochondrial membrane
potential (∆ψm) were studied using flow cytometry 24 h after the CAP treatment. The cells
were plated under the same conditions described for the oxidative stress assays and the
same CAP exposure times were also used.
To study the oxidative stress, reactive oxygen and nitrogen species, as well as antiox-
idant defenses were evaluated. Both cell lines were plated in a 24-well cell culture plate
at a concentration of 1 × 106 cell/mL in a volume of 500 µL/well. This cell concentration
is not physiological. The cells were allowed to adhere, and then were submitted to CAP
treatment 30, 60, and 120 s, times that were selected from the cytotoxicity assays. Upon 2, 6,
and 24 h after treatment the intracellular content of hydrogen peroxide, superoxide radical,
reduced glutathione, and nitric oxide was evaluated by fluorescence. The hydroxyl radical
was also evaluated 24 h after treatment, through the presence of an inhibitor of this reactive
specie, D-mannitol. In this assay, the cells were plated under the conditions described for
the proliferation assays.
2.3. Cell Proliferation Assessment
The metabolic activity was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) assay. MTT is a yellow tetrazolium reagent, that is reduced
with the formation of purple formazan crystals in the presence of dehydrogenase enzymes
located in viable mitochondria [31]. Upon 24, 48, and 72 h after treatment with CAP, MTT
protocol was performed as previously described by our group [32]. The absorbance values
were determined at 570 and 620 nm wavelengths in a spectrophotometer (EnSpire® Multi-
mode Plate Reader, PerkinElmer®). Results are presented as the percentage of metabolic
activity normalized to the control.
To evaluate the protein content, it was used the colorimetric sulphorhodamine B
(SRB) assay, a negatively charged pink aminoxanthine dye that gives a measure of protein
synthesis. The greater the number of cells, the greater amount of dye is taken up, and the
greater the absorbance [33]. Upon 24, 48, and 72 h after treatment with CAP, SRB assay was
performed according to our published study [34]. Absorbance was quantified at 540 nm
with a reference filter of 690 nm in a spectrophotometer (EnSpire® Multimode Plate Reader,
PerkinElmer®). Results are presented as the percentage of protein content normalized to
the control.
2.4. Cell Cycle Analysis
To evaluate the effect of CAP on the progression of the cell cycle in both bladder
carcinoma cell lines, the labeling with propidium iodide (PI) was used. PI has the ability to
interleave in DNA and allows different populations to be obtained in each of the phases
of the cell cycle, but it also interleaves with RNA. Thus, in order to obtain a specific DNA
labeling, it is necessary to remove the RNA enzymatically using RNase [35]. Cells in the S
phase have more DNA than cells in the G0/G1 phase and cells in the G2/M phase have
twice the DNA content than cells in the G0/G1 phase. Sometimes, it is still possible to
identify a cell population in pre-G0/G1 that has less DNA, also called apoptotic peak.
Upon 24 h after CAP treatment, cells were detached and 1 × 106 cells were centrifuged for
5 min at 1300 xG. Cell cycle labeling was performed as previously described [34], using
a PI/RNase solution (Immunostep, PI/RNase). The analysis was performed on a flow
cytometer (FACSCalibur, Becton Dickinson), using an excitation wavelength of 488 nm and
an emission of 640 nm. Results are presented as the percentage of cells identified in each of
the subpopulations: pre-G0/G1, G0/G1, S, and G2/M.
2.5. Viability and Cell Death Profile
To determine the type of cell death induced by CAP in both bladder carcinoma cell
lines, the double labeling with annexin V (AV) marked with FITC (fluorescein isothio-
cyanate) and PI was used. This assay is based on the affinity of AV for phosphatidylserine,
which at the beginning of apoptosis is translocated from the inner layer to the outer layer of
Biology 2021, 10, 41 5 of 19
the plasma membrane, being exposed to the cell surface. PI is used in conjunction with AV
since it is intercalated in DNA in cells that have impaired plasma membrane integrity [36].
This double labeling allows to distinguish viable cells (AV−/PI−) and three different types
of cell death: initial apoptosis (AV+/PI−), late apoptosis/necrosis (AV+/PI+), and necrosis
(AV−/PI+). Upon 24 h after CAP treatment, cells were detached and 1 × 106 cells were
centrifuged for 5 min at 1300 xG. Then, cells were washed with PBS and incubated with
100 µL of binding buffer (0.01 M Hepes (Sigma, H7523), 0.14 M NaCl and 0.25 mM CaCl2
(Sigma, C4901)), 2.5 µL of AV-FITC (Immunostep, ANXVKF), and 1 µL of PI (Immunostep,
ANXVKF) for 15 min at 37 ◦C, in the dark. After incubation, 400 µL of binding buffer was
added and analysis was performed on a flow cytometer (FACSCalibur, Becton Dickinson),
using the excitation wavelength of 488 nm and emission wavelengths of 533 nm for the
AV-FITC and 640 nm for the PI. Results are presented as the percentage of cells identified
in each of the subpopulations: viable cells (V), cells in initial apoptosis (A), cells in late
apoptosis/necrosis (A/N), and cells in necrosis (N).
2.6. Mitochondrial Membrane Potential Analysis
To evaluate the effect of CAP on the potential of the mitochondrial membrane (∆ψm),
the fluorescent probe JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine
iodide) was used. JC-1 is a lipophilic and cationic dye with the ability to form aggregates (A)
or monomers (M), depending on the state of ∆ψm. The lower the aggregates/monomers
(A/M) ratio, the lower the ∆ψm, which indicates mitochondrial dysfunction [37–39]. Upon
24 h after CAP treatment, cells were detached and after wash with PBS, 1 × 106 cells were
labeled with 5 µg/mL of the JC-1 probe (Sigma, T4069) for 15 min at 37 ◦C, in the dark.
Analysis was performed on a flow cytometer (FACSCalibur, Becton Dickinson), using the
excitation wavelength of 590 nm for the aggregates and 530 nm for the monomers. Results
are presented as the variation in the ratio of the aggregates/monomers (A/M) fluorescence
intensities, normalized to the control.
2.7. Reactive Oxygen and Nitrogen Species
The quantification of intracellular peroxides was carried out through the intracellu-
lar oxidation of the non-fluorescent probe DCFH2-DA (2′,7′-dichlorodihydrofluorescein
diacetate), which is internalized in the cells and accumulates preferentially in the cytosol.
After deacetylation by intracellular esterases and oxidation in the presence of peroxide,
a fluorescent product is formed 2′,7′-dichlorofluorescein (DCF) [40,41]. To estimate the
intracellular levels of superoxide radical, the DHE probe (dihydroethidium) was used.
This probe easily crosses the cell membrane and is oxidized by the superoxide radical
to form a fluorescent red compound that is interleaved in DNA [42]. To determine the
intracellular content of nitric oxide, the DAF-FM Diacetate (4-amino-5-methylamino-2′,7′-
difluorofluorescein diacetate) probe was used. This probe crosses the cell membrane and is
deacetylated by intracellular esterase enzymes, forming the compound DAF-FM. Subse-
quently, this compound reacts with the nitric oxide molecule, which allows the emission of
fluorescence [41].
Upon 2, 6, and 24 h after CAP treatment, 5 × 105 cells were centrifuged for 5 min at
1300 xG. Then the cells were washed with PBS, centrifuged again for 5 min at 1300 xG
and 1 mL of PBS was added. The cells were incubated with 5 µM of the probe DCFH2-DA
(Invitrogen, D-399) for 45 min or with 2 µM of the probe DHE (Sigma, D7008) for 15 min
or with 1 µM of the probe DAF-FM Diacetate (Sigma, D2321) for 1 h at 37 ◦C, in the dark.
Finally, the cells were washed with PBS, by centrifugation for 5 min at 1300 xG. The reading
was performed on a spectrophotometer (EnSpire® Multimode Plate Reader, PerkinElmer®)
with excitation wavelengths of 485 nm and emission of 528 nm for DCFH2-DA, 530 nm and
emission of 645 nm for DHE and 495 nm and emission of 515 nm for DAF-FM Diacetate.
Results are presented as the mean of the fluorescence intensities (MFIs) normalized to
the control.
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The hydroxyl radical was indirectly evaluated through the use of an inhibitor, D-
mannitol, a scavenger for the hydroxyl radical [43,44]. The cells were plated under the
same conditions described for the cytotoxicity assays and 2 h before CAP treatment the
medium in each well was removed and replaced by fresh medium containing 40 mM of
D-mannitol (Sigma, M4125), based on the optimal inhibition concentration described in
the literature [45]. In this assay, two controls were used, the negative control consisting of
cells where no compound was administered (C), and the mannitol control consisting of
cells treated only with mannitol (Cm). Upon 24 h after treatment, cell proliferation was
assessed by the MTT assay described previously. Results are presented as the percentage of
metabolic activity normalized to the mannitol control (Cm). The percentage data obtained
allowed plotting exposure time-response curves.
2.8. Antioxidant Defenses
To determine the intracellular content of reduced glutathione (GSH), a non-enzymatic
antioxidant defense, the fluorescent orange mercury compound was used. The probe reacts
quickly with GSH, giving rise to a compound that emits fluorescence [46]. Upon 2, 6, and
24 h after CAP treatment 5 × 105 cells were centrifuged for 5 min at 1300 xG. Then cells
were washed with PBS, centrifuged again for 5 min at 1300 xG and 1 mL of PBS was added.
The cells were incubated with 10 µM of orange mercury (Sigma, M7750) for 15 min at
37 ◦C, in the dark. Finally, the cells were centrifuged for 5 min at 1300 xG and the reading
was performed on a spectrophotometer (EnSpire® Multimode Plate Reader, PerkinElmer®)
with excitation wavelengths of 485 nm and emission of 590 nm. The results are presented
as the MFIs normalized to the control.
2.9. Statistical Analysis
Statistical analysis was performed using GraphPad Prism software version 7.00 for
Windows (GraphPad Software, La Jolla, CA, USA). The evaluation of the normality of
distribution of the quantitative variables was carried out according to the normality test of
D’Agostino Pearson. Parametric tests were used in case of a normal distribution and non-
parametric tests were used otherwise. Outliers were identified using the ROUT method.
The comparison of the different groups of exposure times to CAP was made according
to the one-factor Analysis of Variance (ANOVA) test (in the case of normal distribution)
or according to the Kruskal Wallis test (otherwise). For multiple comparisons, in case of
normal distribution, Dunnett test was used to compare each mean of the exposure time
groups with the mean of the control group and Tukey test to compare all the means of all
groups with each other, in case of non-normal distribution it was used Dunn’s test. To
compare the different times after CAP treatment considering the different exposure times,
the two-way ANOVA test was used, using the Tukey test for multiple comparisons. A
significance of 0.05 was considered for all comparisons.
3. Results
In this study, we investigated the effects of CAP in two bladder cancer cell lines, the
HT-1376 (grade III) and the TCCSUP (grade IV). Our focus was to assess cell proliferation,
cell viability, and cell death profile, as well as the changes in the cell cycle, the mitochondrial
membrane potential, and oxidative stress. In this context, we evaluated the reactive oxygen
and nitrogen species involved in the CAP mechanism of action. To make it clearer, from
now on, the period of time to which the cells are exposed to treatment with CAP will
be called “exposure time,” and the period of time between the end of the exposure to
CAP until the evaluation of any parameter at the cellular level will be called “time after
CAP treatment.”
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3.1. CAP Decreases Cell Proliferation
In order to evaluate whether CAP inhibited cell proliferation, the two bladder cancer
cell lines were exposed to CAP treatment for 15, 30, 60, 90, and 120 s. MTT and SRB assays
were performed 24, 48, and 72 h after CAP treatment.
3.1.1. Cell Metabolic Activity
In the MTT assay, the metabolic activity decreased in both cell lines depending on the
exposure time and time after CAP treatment, as shown in Figure 1a,b. The TCCSUP cell
line proved to be more sensitive to CAP treatment when compared to the HT-1376 cell line.
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Comparing the results of the different exposure times with the control, for 24 h after
CAP treatment, there was only a significant (p = 0.0002) decrease in metabolic activity with
a 120 s of exposure time in the HT-1376 cell line (Figure 1a), while in the TCCSUP cell line,
there was a significant (p < 0.0001) decrease in metabolic activity with an exposure equal to
or higher than 60 s (Figure 1b).
For 48 h after CAP treatment, the longer the exposure time, the lower the metabolic
activity with differences statistically significant for exposure times of 90 (p = 0.0012) and
120 (p < 0.0001) seconds in the case of the HT-1376 cell line (Figure 1a) and exposure times
equal to (p = 0.0096) or higher than (p < 0.0001) 15 s for TCCSUP cell line (Figure 1b). The 90
and 120 s of exposure drastically decreased the TCCSUP metabolic activity to 1.45 ± 0.35%
(p < 0.0001) and 0.91 ± 0.15% (p < 0.0001), respectively.
Likewise, for 72 h after CAP treatment, in the HT-1376 cell line, an exposure time-
dependent response was observed, with differences statistically significant for exposure
times equal to (p = 0.0040) or higher than (p < 0.0001) 15 s of exposure (Figure 1a). With 120 s
exposure, the metabolic activity decreased to 8.72 ± 1.99% (p < 0.0001). In the TCCSUP cell
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line, 15 s of exposure was enough to significantly (p < 0.0001) decrease the cells metabolic
activity (Figure 1b). For exposure times of 60, 90, and 120 s, the metabolic activity decreased
drastically to less than 1% (p < 0.0001).
Regarding the differences observed between the times after CAP treatment, results
show that cell metabolic activity decreases in a time after CAP treatment-dependent manner.
For the HT-1376 cell line, only 72 h after CAP treatment with exposure times to CAP equals
to or higher than 60 s, it is possible to obtain a decrease in the metabolic activity greater
than 50%. Moreover, 72 h after CAP treatment it was observed a significant (p < 0.0001)
decrease in cell metabolic activity compared with the 24 and 48 h after CAP treatment. The
TCCSUP cell line shows to be more sensitive to CAP treatment since, only 24 h after CAP
treatment and with an exposure time of 90 s, its metabolic activity is reduced by more than
50%. Upon 48 and 72 h after CAP treatment and with exposure times of 60 (for 72 h after
CAP treatment), 90 and 120 s (for 48 and 72 h after CAP treatment), the metabolic activity
decreases to values close to 0% (Figure 1b).
3.1.2. Protein Content
Regarding the SRB assay, the protein content decreased in both cell lines depending
on the exposure time and time after CAP treatment, as shown in Figure 1c,d. TCCSUP cell
line proved to be more sensitive to CAP treatment, corroborating MTT results.
When comparing the exposure times with control, for 24 h after CAP treatment, there
was no significant decrease in protein content at any time of exposure in the HT-1376 cell
line (Figure 1c). On the other hand, in the TCCSUP cell line, the longer the exposure time,
the lower the protein content with differences statistically significant for exposure times
equal to (p = 0.0195) or higher than (p < 0.0001) 30 s of exposure (Figure 1d).
For 48 h after CAP treatment, the protein content of the HT-1376 cell line significantly
(p < 0.0001) decreased only with an exposure time of 120 s (Figure 1c). Meanwhile, in
the TCCSUP cell line, the longer the exposure time, the lower the protein content with
differences statistically significant (p < 0.0001) for all exposure times (Figure 1d). The 90 and
120 s of exposure time decreased drastically the protein content to 4.04 ± 0.27% (p < 0.0001)
and 4.81 ± 0.26% (p < 0.0001) respectively.
Lastly, for 72 h after CAP treatment, the longer the exposure time, the lower the protein
content with differences statistically significant for exposure times equals to (p = 0.0077) or
higher than (p < 0.0001) 30 s of exposure in the HT-1376 cell line (Figure 1c). The 120 s of
exposure time reduced the protein content remarkably to 2.56 ± 0.30% (p < 0.0001). As for
the TCCSUP cell line, all exposure times significantly (p < 0.0001) decreased the protein
content to less than 50% (Figure 1d).
As demonstrated in the MTT assay, the time after CAP treatment, together with the
exposure time, influences the decrease in the cell metabolic activity and also influences the
protein content. In the case of the HT-1376 cell line, only 72 h after CAP treatment together
with 60, 90, and 120 s of exposure time were capable to decrease the protein content near to
or below 50% (Figure 1c). Meanwhile, in the TCCSUP cell line, 24 h after CAP treatment
with 90 and 120 s of exposure time were enough to decrease the protein content below
50%, which demonstrates that the TCCSUP cell line is more sensitive to CAP treatment. In
addition, with 90 and 120 s of exposure times, 48 and 72 h after CAP treatment, CAP had a
similar effect on the protein content, lowering it to values close to 3% (Figure 1d).
Of these assays, the 30, 60, and 120 s of exposure times were selected for the remaining
experiments.
3.2. CAP Decreases Cell Viability
The effects of CAP in the viability and cell death profile of the HT-1376 and TCCSUP
cell lines were determined, by flow cytometry, 24 h after CAP treatment, using a double
labeling with AV and PI. Both cell lines were exposed to CAP treatment for 30, 60, and 120 s.
As shown in Figure 2a,b, the longer the exposure time, the lower the cell viability with
statistically significant differences for exposure times equal to (p = 0.0320) or higher than
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(p < 0.0001) 30 s for HT-1376 cell line (Figure 2a), and for all exposure times (p < 0.0001)
for TCCSUP cell line (Figure 2b). Once more, the TCCSUP cell line proved to be more
sensitive to CAP treatment, since with a 60 s of exposure time the cell viability decreased to
29.07 ± 3.54%, while in the HT-1376 cell line, twice the exposure time (120 s) only decreased
the cell viability to 34.93 ± 6.12%. The decrease in cell viability was accompanied by an
increase of cells in apoptosis, late apoptosis, and necrosis. In the HT-1376 cell line, the cells
in late apoptosis (p < 0.0001), as well as the necrotic cells (p = 0.0040) significantly increased
with 120 s of exposure time (Figure 2a). In the TCCSUP cell line, for exposure times equal
to (p = 0.0495) or higher than (p = 0.0003) 60 s, the percentage of cells in late apoptosis
significantly increased, as well as the percentage of cells in necrosis (p = 0.0027) for 120 s of
exposure time (Figure 2b). In both cell lines, there was no predominant type of cell death
for shorter exposure times. However, for longer exposure times, necrosis was the most
observed type of cell death.




Figure 2. CAP treatment decreases cell viability, induces cell cycle alterations, and depolarization of the Δψm of HT1376 
(a,c,e) and TCCSUP (b,d,e) cell lines in a time of exposure-dependent manner. The viability and cell death profile (n ≥ 4 
independent experiments in triplicate), cell cycle progression (n ≥ 3 independent experiments in triplicate), and the Δψm 
(n = 4 independent experiments in triplicate) were evaluated by flow cytometry 24 h after CAP treatment. (a,b) Results of 
viability and cell death profile are expressed as the mean ± SEM of the percentage of viable cells (V), cells in initial apop-
tosis (A), cells in late apoptosis/necrosis (A/N), and cells in necrosis (N). (c,d) Results of cell cycle progression are expressed 
as the mean ± SEM of the percentage of cells identified in each phase: pre-G0/G1, G0/G1, S, and G2/M. (e) Results of Δψm are 
expressed as the mean ± SEM of aggregates/monomers (A/M) ratio normalized to control. p value was reported as *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Representative dot plots, from the HT-1376 cell line, of the viability and cell 
death profile, cell cycle analysis, and the Δψm assays are presented in Figures S1‒3 in the supplementary materials. 
3.3. CAP Induces Alterations on the Cell Cycle 
The evaluation of the effect of CAP on the progression of the cell cycle was deter-
mined 24 h after CAP treatment, by flow cytometry, using the labeling with PI. Both cell 
lines were exposed to CAP treatment for 30, 60, and 120 s. 
As shown in Figure 2c and d, cell cycle analysis indicates that CAP induced cell cycle 
arrest of both cell lines in S phase. For the HT-1376 cell line, there was a significant (p < 
0.0001) increase of cells in the S phase for all exposure times (Figure 2c). Regarding the 
TCCSUP cell line, there was a significant (p < 0.0001) increase of cells in the S phase for 
exposure times of 30 and 60 s. For 120 s the cells in S phase slightly increase (p = 0.0246) 
Figure 2. CAP treatment decreases cell viability, induces cell cycle alterations, and depolarization of the ∆ψm of HT1376
(a,c,e) and TCCSUP (b,d,e) cell lines in a time of exposure-dependent manner. The viability and cell death profile (n ≥ 4
independent experiments in triplicate), cell cycle progression (n ≥ 3 independent experiments in triplicate), and the ∆ψm
(n = 4 i dependent experiments in tripl cate) wer valuated fl cytometry 24 h after CAP treatment. (a,b) Results of
viability and cell death profile are expressed as the mean ± SEM of the percentage of viable cells (V), cells in initial apoptosis
(A), cells in late apoptosis/necrosis (A/N), and cells in necrosis (N). (c,d) Results of cell cycle progression are expressed as
the mean ± SEM of the percentage of cells identified in each phase: pre-G0/G1, G0/G1, S, and G2/M. (e) Results of ∆ψm
are expressed as the mean ± SEM of aggregates/mo omers (A/M) ratio normalized to co tr l. p value was reported as
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. Representative dot plots, from the HT-1376 cell line, of the viability and
cell death profile, cell cycle analysis, and the ∆ψm assays are presented in Figures S1-S3 in the Supplementary Materials.
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3.3. CAP Induces Alterations on the Cell Cycle
The evaluation of the effect of CAP on the progression of the cell cycle was determined
24 h after CAP treatment, by flow cytometry, using the labeling with PI. Both cell lines
were exposed to CAP treatment for 30, 60, and 120 s.
As shown in Figure 2c,d, cell cycle analysis indicates that CAP induced cell cycle arrest
of both cell lines in S phase. For the HT-1376 cell line, there was a significant (p < 0.0001)
increase of cells in the S phase for all exposure times (Figure 2c). Regarding the TCCSUP
cell line, there was a significant (p < 0.0001) increase of cells in the S phase for exposure
times of 30 and 60 s. For 120 s the cells in S phase slightly increase (p = 0.0246) compared
to control. In addition, in the TCCSUP cell line, after 120 s of CAP treatment, there is a
tendency for an increase in the pre-G0/G1 apoptotic peak (Figure 2d).
3.4. CAP Induces Depolarization of the Mitochondrial Membrane Potential
In order to understand whether CAP induces mitochondrial dysfunction, the effects
of CAP in the mitochondrial membrane potential (∆ψm) in the two cell lines were deter-
mined by flow cytometry, 24 h after CAP treatment, using the probe JC-1. The cells were
exposed to CAP treatment for 30, 60, and 120 s. It should be noted that the lower the
aggregates/monomers (A/M) ratio, the lower the ∆ψm, which indicates mitochondrial
dysfunction.
In both cell lines, the longer the exposure time, the lower the ∆ψm with differences
statistically significant for exposure times of 60 and 120 (p < 0.05) seconds in the case of the
HT-1376 cell line and for all exposure times (p < 0.0001) in the TCCSUP cell line (Figure 2e).
The TCCSUP cell line once more proved to be more sensitive to CAP treatment, since 120 s
of exposure decreased the ∆ψm 2 times in the HT-1376 cell line, while in the TCCSUP cell
line a quarter of that exposure time (30 s) also decreased the ∆ψm 2 times. Furthermore,
120 s of exposure drastically decreased the ∆ψm 5.9 times in the TCCSUP cell line.
3.5. CAP Treatment Induces Alterations in Oxidative Stress of Both Cell Lines
In order to evaluate the alterations induced by CAP treatment in the oxidative stress
by reactive oxygen and nitrogen species involved in the CAP mechanism of action, the
two bladder cancer cell lines were exposed to CAP treatment for 30, 60, and 120 s. The
intracellular content of peroxides, superoxide radical, as well as GSH, and nitric oxide
were evaluated 2, 6, and 24 h after CAP treatment. In addition, the influence of hydroxyl
radical was evaluated 24 h after CAP treatment through the presence of an inhibitor of this
reactive specie, D-mannitol.
3.5.1. CAP Decreases the Intracellular Content of Peroxides
In the HT-1376 cell line, the intracellular content of peroxides significantly (p = 0.0320)
increased compared to control with 30 s of exposure and 2 h after CAP treatment. However,
for longer exposure times and longer times after CAP treatment, intracellular content of
peroxides significantly (p < 0.05) decreased (Figure 3a).
Regarding the TCCSUP cell line, for 2 and 6 h after CAP treatment, the intracellular
content of peroxides significantly (p < 0.05) decreased compared to control with 60 and
120 s of exposure. For 24 h after CAP treatment and with all exposure times, there was
a significant (p < 0.0001) decrease to approximately half of the intracellular content of
peroxides, comparing with control (Figure 3b).




Figure 3. In both HT-1376 and TCCSUP cell lines, the intracellular content of peroxides (a,b) decreased and the superoxide 
radical (c,d) increased, while the nitric oxide increased in the HT-1376 cell line (e) and decreased in the TCCSUP cell line 
(f), depending on the exposure time and time after CAP treatment. Intracellular contents of peroxides (n ≥ 4 independent 
experiments in triplicate), superoxide radical (n ≥ 4 independent experiments in triplicate), and nitric oxide (n ≥ 4 inde-
pendent experiments in triplicate) were evaluated by fluorescence using the probes DCFH2-DA, DHE, and DAF-FM Di-
acetate, respectively, 2, 6, and 24 h after CAP treatment. Results are expressed as the mean ± SEM of the mean fluorescence 
intensities (MFIs) normalized to control. Statistical differences between exposure times within 2 or 6 or 24 h after the CAP 
treatment are represented with “*” with horizontal bars and the differences between the exposure times and the control 
within 2 or 6 or 24 h after the CAP treatment are represented with “*” on top of the respective column, being p value 
reported as *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
Regarding the TCCSUP cell line, for 2 and 6 h after CAP treatment, the intracellular 
content of peroxides significantly (p < 0.05) decreased compared to control with 60 and 
120 s of exposure. For 24 h after CAP treatment and with all exposure times, there was a 
significant (p < 0.0001) decrease to approximately half of the intracellular content of per-
oxides, comparing with control (Figure 3b). 
3.5.2. CAP Increases the Intracellular Content of Superoxide Radical 
Figure 3. In both HT-1376 and TCCSUP cell lines, the intracellular content of peroxides (a,b) decreased and the superoxide
radical (c,d) increased, while the nitric oxide increased in the HT-1376 cell line (e) and decreased in the TCCSUP cell line
(f), depen ing on the exposure time and time after CAP treatment. I ll lar contents of peroxides (n ≥ 4 independent
experiments in triplicate), superoxide radical (n 4 independent experime ts in triplicate), and nitric oxide (n ≥ 4
independent experiments in triplicate) were evaluated by fluorescence using the probes DCFH2-DA, DHE, and DAF-FM
Diacetate, respectively, 2, 6, and 24 h after CAP treatment. Results are expressed as the mean± SEM of the mean fluorescence
intensities (MFIs) normalized to control. Statistical differences between exposure times within 2 or 6 or 24 h after the CAP
treatmen are represented with “*” with horizont l bars and the differences between the exposure times and the control
within 2 or 6 or 24 h after the CAP treatment are represented with “*” on top of the respective column, being p value
reported as * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
3.5.2. CAP Increases the Intracellular Content of Superoxide Radical
CAP treatment induced an increase of the intracellular content of superoxide radical
for short times after CAP treatment in both cell lines, while for longer times after CAP
treatment, it induced a decrease in the TCCSUP cell line.
In the HT-1376 cell li e, the int acellular cont nt of superoxide radical significantly
(p = 0.0459) increased compared to control with 60 s of exposure and 2 h after CAP treatment,
while no statistical differences were observed in the remaining exposure times and times
after CAP treatment (Figure 3c).
Regarding the TCCSUP cell line, for shorter times after CAP treatment (2 and 6 h),
the longer the exposure time, the higher the intracellular content of superoxide radical
with differences statistically significant for exposure times of 60 (p < 0.05) and 120 (p < 0.01)
seconds relative to control. However, for the longest time after CAP treatment (24 h),
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superoxide levels significantly decreased (p = 0.0480) compared to control with 120 s of
exposure. (Figure 3d).
3.5.3. Intracellular Content of Nitric Oxide
CAP treatment induced an increase in the intracellular content of nitric oxide for short
times after CAP treatment in the HT-1376 cell line, while, in the TCCSUP cell line the
intracellular content of nitric oxide decreased for longer times after CAP treatment.
In the HT-1376 cell line, the intracellular content of nitric oxide significantly (p < 0.05)
increased compared to control with 60 and 120 s of exposure and with both 2 and 6 h
after CAP treatment, while for 24 h after CAP treatment no differences were observed
(Figure 3e).
Regarding the TCCSUP cell line, the intracellular content of nitric oxide significantly
(p < 0.05) decreased compared to control with 60 and 120 s of exposure and with both 6 and
24 h after CAP treatment, while for 2 h after CAP treatment no differences were observed
(Figure 3f).
3.5.4. Influence of Hydroxyl Radical
CAP treatment together with a scavenger of the hydroxyl radical decreased the
metabolic activity in both cell lines.
In the HT-1376 cell line, the combined treatment significantly (p < 0.01) decreased the
metabolic activity with 60 and 120 s of exposure time compared to CAP treatment alone
(Figure 4a). The same was true for the TCCSUP cell line (p < 0.05), but with 30, 60, and
120 s of exposure time (Figure 4b). It is of note that D-mannitol alone did not interfere with
the metabolic activity of the two cell lines (results not shown).




Figure 4. CAP treatment together with D-mannitol decreased the metabolic activity in both HT-1376 (a) and TCCSUP (b) 
cell lines. No differences were observed in the intracellular content of GSH in both HT-1376 (c) and TCCSUP (d) cell lines. 
The hydroxyl radical was indirectly evaluated using D-mannitol. The cells were treated with CAP or CAP with D-mannitol 
(CAP + Mannitol), and the cell proliferation was accessed by MTT 24 h after CAP treatment (n = 5 independent experiments 
in triplicate). Exposure time-response curves were plotted, and the results are expressed as the mean ± SEM of the per-
centage of metabolic activity normalized to control. Statistical differences between CAP and CAP + Mannitol are repre-
sented, being p value reported as *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Intracellular content of GSH was evaluated 
by fluorescence using the fluorescent orange mercury compound, 2, 6, and 24 h after CAP treatment (n ≥ 4 independent 
experiments in triplicate). Results are expressed as the mean ± SEM of the MFIs normalized to control. 
3.5.5. CAP does not Affect the Intracellular Content of GSH 
As shown in Figure 4c,d, CAP treatment did not induce any alterations in the intra-
cellular content of GSH in both cell lines, since there were no statistically significant dif-
ferences between control and the CAP exposure times, for any time after CAP treatment. 
4. Discussion 
The high incidence and mortality of bladder cancer, as well as the lack of new treat-
ment options combined with the deficiency in efficacy and safety of the existing ones, has 
forced the development of new, more effective, and safe approaches for the treatment of 
this cancer [1,47]. 
Several studies demonstrated that CAP has the ability of inducing antitumor effects 
on a variety of cancer types, such as hepatoma [48], lymphoma [49], prostate cancer [50], 
gastric cancer [51], breast cancer [52], brain cancer [53], ovarian cancer [54], skin cancer 
[55], head and neck cancer [56], colorectal cancer [57], and lung cancer [58]. For bladder 
cancer, Mohades et al. already demonstrated a decrease in cell viability and induction of 
apoptosis after CAP treatment but only in one cell line [25], while Keidar et al. demon-
strated tumor ablation in a mouse xenograft model of bladder cancer [26]. In these two 
studies, only the SCaBER cell line was used. This cell line is representative of squamous 
cell carcinoma, which only accounts for 2%–5% of bladder tumors [59]. The present study 
demonstrates the promising application of CAP in bladder cancer treatment through sev-
eral experiments carried out on two bladder cancer cell lines belonging to different stages 
of the disease.  
Figure 4. CAP treatment together with D-mannitol decreased the metabolic activity in both HT-1376 (a) and TCCSUP
(b) cell lines. No differences were observed in the intracellular content of GSH in both HT-1376 (c) and TCCSUP (d) cell
lines. The hydroxyl radical was indirectly evaluated using D-mannitol. The cells were treated with CAP or CAP with
D-mannitol (CAP + Mannitol), and the cell proliferation was accessed by MTT 24 h after CAP treatment (n = 5 independent
experiments in triplicate). Exposure time-respons curves were plotted, and the result are expr ssed as the mean ± SEM of
the percentage of metabolic activity normalized to control. Statistical differ nc s betwee CAP and CAP + Mannitol are
represented, being p value reported as * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Intracellular content of GSH was evaluated
by fluorescence using the fluorescent orange mercury compound, 2, 6, and 24 h after CAP treatment (n ≥ 4 independent
experiments in triplicate). Results are expressed as the mean ± SEM of the MFIs normalized to control.
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3.5.5. CAP Does Not Affect the Intracellular Content of GSH
As shown in Figure 4c,d, CAP treatment did not induce any alterations in the in-
tracellular content of GSH in both cell lines, since there were no statistically significant
differences between control and the CAP exposure times, for any time after CAP treatment.
4. Discussion
The high incidence and mortality of bladder cancer, as well as the lack of new treatment
options combined with the deficiency in efficacy and safety of the existing ones, has forced
the development of new, more effective, and safe approaches for the treatment of this
cancer [1,47].
Several studies demonstrated that CAP has the ability of inducing antitumor effects
on a variety of cancer types, such as hepatoma [48], lymphoma [49], prostate cancer [50],
gastric cancer [51], breast cancer [52], brain cancer [53], ovarian cancer [54], skin cancer [55],
head and neck cancer [56], colorectal cancer [57], and lung cancer [58]. For bladder cancer,
Mohades et al. already demonstrated a decrease in cell viability and induction of apoptosis
after CAP treatment but only in one cell line [25], while Keidar et al. demonstrated tumor
ablation in a mouse xenograft model of bladder cancer [26]. In these two studies, only the
SCaBER cell line was used. This cell line is representative of squamous cell carcinoma,
which only accounts for 2%–5% of bladder tumors [59]. The present study demonstrates
the promising application of CAP in bladder cancer treatment through several experiments
carried out on two bladder cancer cell lines belonging to different stages of the disease.
Considered together the results for MTT and SRB assays, we can conclude that CAP
treatment significantly reduces cell proliferation in a time of exposure- as well as a time after
CAP treatment-dependent manner. The same was observed by Wang et al. and Guerrero-
Preston et al. in breast cancer and head and neck cancer cell lines, respectively [56,60]. We
can also see that the effects of CAP are also dependent on the cell line, and in this case, it
proved to be more effective on the high-grade cell line (TCCSUP). Therefore, the optimal
time of exposure for maximum efficacy must consider the cell line and its grade.
According to the literature, CAP treatment can induce autophagy [50], senescence [21,61],
apoptosis, or necrosis [62–65] in a time of exposure-dependent manner. However, other
factors may also be involved in the cell fate after CAP treatment, such as cell type and
plasma source [17]. The CAP treatment when applied to bladder cancer cell lines demon-
strated an induction of apoptosis and necrosis. For shorter exposure times, there was no
predominant type of cell death, while, for longer exposure times, there was an increase
of necrosis. What could be explained by the oxidative stress impairment is that a more
intense oxidative stimulus is associated with necrosis.
After evaluating the alterations on the cell cycle, CAP treatment induced cell cycle
arrest in the S phase in both cell lines. Vandamme et al. as already demonstrated cell cycle
arrest in S and G2/M phases [66]. Volotskova et al. observed alterations in the S phase,
but this study and other authors have reported cell cycle arrest mostly in the G2/M phase
induced by CAP treatment [67,68]. Interestingly, the cell proliferation decrease previously
observed after MTT and SRB assays should be translated in a cell cycle blockade in G0/G1
phase, which was not observed. According to the Catalogue of Somatic Mutations in
Cancer (COSMIC) (https://cancer.sanger.ac.uk/cell_lines) both cell lines used express RB1
and TP53 mutations. RB1 and P53 proteins are involved in major signaling pathways that
regulate G1 phase, influencing the decision on whether or not a cell enters in S phase [69].
However, the presence of mutations in genes encoding key cell cycle proteins, like RB1
and P53 can lead to aberrant activation of CDKs and to failures in activating cell cycle
checkpoints [70]. The cell cycle arrest in S phase could be explained by the ability of
CAP to induce DNA damage, including DNA double-strand breaks that will cause DNA
fragmentation preventing the cells from passing the DNA replication phase and/or making
this phase slower [17]. TCCSUP cells demonstrated a completely different profile in the
120 s of exposure, this could be due to 85% of the cells were dead and only 15% were viable
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and reflected this cell cycle profile. Here it is possible to see an increase in the apoptotic
peak that may indicate cell death by apoptosis.
As previously reported, CAP treatment induces depolarization of the mitochondrial
membrane and thus mitochondria-mediated cell death [20,71]. In our results, we also
observed depolarization of the mitochondrial membrane in both cell lines, being the
TCCSUP cells the ones that suffered the greatest decrease in the mitochondrial membrane
potential, corroborating the results that demonstrated a higher cell death induction in this
cell line. These results demonstrate one of the pathways by which CAP induces cell death.
CAP has the ability to selectively induce cell death in cancer cells, in detriment of the
normal ones [15–17,72,73]. This selectivity is mainly due to the imbalance in the oxidative
stress caused by CAP and to the differences between normal and cancer cells that facilitates
RONS penetration into the cell, such as the higher levels of aquaporins in cancer cells, and
the membrane lipid structure, which is influenced by the lower levels of cholesterol in
cancer cells [16,17,72].
In the present study, this imbalance in the cellular stress caused by CAP was studied
in order to understand which RONS plays a key role in the CAP mechanism of action. We
observed that the intracellular content of peroxides decreased in both cell lines depending
on the exposure time and time after CAP treatment, contrary to what has been reported
by other authors, that have seen an increase in the intracellular content of peroxides after
CAP treatment [74,75]. This decrease may be justified by the conversion of the peroxides,
namely, hydrogen peroxide, in other more reactive species such as hydroxyl radical, or by
their possible detoxification by antioxidant defenses [76]. To prove the possible implication
of hydroxyl radical in CAP treatment, cells were treated with both CAP and a scavenger of
this reactive specie (mannitol). Compared to the CAP treatment alone, the combination
of CAP plus the hydroxyl radical scavenger decreased the metabolic activity, which may
indicate that this reactive specie is not involved in the CAP mechanism of action. On
the contrary, Kaushik et al. reported a significant protective effect of cancer cell lines by
mannitol against CAP treatment, demonstrating the influence of the hydroxyl radical [75].
Thus, this indirect measure to assess the influence of the hydroxyl radical is not the most
suitable, because inhibiting a reactive specie will influence the behavior and formation of
the remaining ones and induce an imbalance in the oxidative stress itself. More studies
must be done in the future.
On the other hand, the intracellular content of superoxide radical increased for shorter
times after CAP treatment in both cell lines, being more evident in the TCCSUP cells. These
results demonstrate that the superoxide radical may be an important player in the CAP
mechanism of action. Superoxide radical can be converted into hydrogen peroxide or can
react with nitric oxide and form peroxynitrite radical that is a powerful oxidant capable
of inducing membrane damage, DNA fragmentation, lipid peroxidation, cytochrome C
release, and, as a consequence, apoptosis and necrosis [64,76,77].
Regarding nitric oxide, our results demonstrate an increase in the intracellular content
of nitric oxide in the HT-1376 cells for shorter times after CAP treatment, while in the
TCCSUP cells there was a decrease for longer times after CAP treatment. On one hand, as
mentioned above, nitric oxide can be involved in the formation of peroxynitrite radical,
and, on the other hand, it can have antitumor effects itself, but the mechanisms by which
nitric oxide exerts its cytotoxic effects are not entirely clear [17]. Xia et al. demonstrated an
increase in the intracellular content of nitric oxide between 3 and 12 h after CAP treatment,
as well as an increase of iNOS expression in melanoma cell lines [78].
After evaluating the intracellular content of GSH, an antioxidant defense, the results
demonstrated no differences between control and CAP exposure times, for any time after
CAP treatment. In contrast, Ishaq et al. demonstrated, in melanoma cells, a decrease in
the intracellular content of GSH depending on the CAP exposure time [74]. These results
demonstrate that the tumor cells were unable to activate their antioxidant machinery to
combat oxidative stress induced by CAP and that the decrease in intracellular content of
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peroxides is not entirely due to their detoxification by the antioxidant defense GSH, but
perhaps by the conversion of this reactive specie in others.
Taken into account the complexity involved in the cell oxidative stress, it is important
and mandatory to evaluate other reactive species like the peroxynitrite radical mentioned
before, and the other antioxidant defenses, in order to understand how the imbalance in
the oxidative stress caused by CAP treatment mediates cell death response. In addition to
assessing intracellular content, it is of utmost importance to evaluate the presence of RONS
in the extracellular environment in order to comprehend which RONS are delivered by
CAP to the cells and which ones play a key role in the CAP mechanism of action.
So far, the present study is the first one to study the effects of CAP treatment in two
different bladder cancer cell lines and to demonstrate the greater sensitivity of the higher-
grade cell line to CAP treatment. However, more detailed studies highlighting the effects
of CAP in bladder cancer and normal cells are needed, in order to completely understand
the whole picture of CAP treatment against bladder cancer. With good results, in the future,
CAP-based therapies might be an alternative or adjunctive to the actual standard of care.
Their applications may be held by different ways. For example, PAM could have a place as
sole adjuvant treatment, or as a replacement to saline in the surgical irrigation, or even in
the post-operative irrigation. On the other hand, CAP could be applied after a cystectomy
or a nephroureterectomy, directly on the surgical bed, to treat microscopic positive margins.
5. Conclusions
In our work, we demonstrated the effects of CAP on two bladder cancer cell lines,
corresponding to two different stages of the disease. We found a decrease in metabolic
activity and protein content for both cell lines. Additionally, there was a significant decrease
in cell viability and a cell cycle arrest in both cell lines, mainly in the S phase. One of the
main mechanisms of action described for CAP is RNOS production. In the present work,
we observed an increase in superoxide and nitric oxide, without changes in GSH levels and
with a decrease in peroxide values. The conversion of these reactive species to others such
as peroxynitrite is very likely. Another CAP known mechanism of action is the decrease
in the mitochondrial membrane potential, which occurred significantly in both cell lines.
Some of the effects described are time- (both exposure time and time after CAP treatment)
dependent.
There is a need to develop new treatments for bladder tumors. CAP-based therapies
may be an alternative in the future. This work is one of the firsts to demonstrate possible
antitumoral effects of CAP in urothelial neoplasms, being more pronounced in the more ad-
vanced disease cell line (TCCSUP). More works are needed to know better the antitumoral
mechanisms and to establish the optimal exposure time to each stage of the disease.
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